Nonprofits receive FDA approval for Chagas drug; Gilead’s buyout of Kite will put it back in pricing fray; most cancer patients don’t receive fertility info
Five things for pharma marketers to know: Tuesday, August 29, 2017
Amgen publishes study assessing cost-effectiveness of Repatha; Brilinta reduces death in patients with heart-attack history; Roche drug gets priority review
Five things for pharma marketers to know: Wednesday, August 23, 2017
Doctors fret about price of Novartis’ experimental CAR-T therapy; study finds digital pillboxes don’t improve adherence; India awards Pfizer vaccine patent
Express Scripts to limit opioid coverage; Novo’s diabetes drug lowers glucose levels in trial; startup aims to give doctors access to a patient’s total costs
Five things for pharma marketers to know: Wednesday, August 16, 2017
Gottlieb criticizes drugmakers for ‘gaming the system’ on generics; investors ignore Trump’s pharma criticism; docs are more supportive of single payer
Frazier’s call earns him praise, rare for a pharma CEO